Fusion Pharmaceuticals’ (FUSN) Hold Rating Reaffirmed at TD Cowen

TD Cowen restated their hold rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN) in a research note published on Tuesday morning, Benzinga reports.

Several other research firms also recently weighed in on FUSN. B. Riley downgraded Fusion Pharmaceuticals from a buy rating to a neutral rating and boosted their target price for the company from $13.00 to $23.00 in a research report on Wednesday, March 20th. William Blair downgraded Fusion Pharmaceuticals from an outperform rating to a market perform rating in a research report on Tuesday, March 19th. Raymond James reissued a market perform rating on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. Royal Bank of Canada reissued a sector perform rating and set a $21.00 target price (up previously from $16.00) on shares of Fusion Pharmaceuticals in a research report on Wednesday, March 20th. Finally, SVB Leerink reissued a market perform rating and set a $21.00 target price (up previously from $17.00) on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. Thirteen analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, Fusion Pharmaceuticals currently has a consensus rating of Hold and a consensus price target of $20.25.

Fusion Pharmaceuticals Stock Performance

NASDAQ:FUSN opened at $21.26 on Tuesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 15.01 and a quick ratio of 15.01. Fusion Pharmaceuticals has a 1 year low of $2.31 and a 1 year high of $21.55. The stock’s 50 day simple moving average is $15.48 and its two-hundred day simple moving average is $9.54. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -14.46 and a beta of -0.73.

Fusion Pharmaceuticals (NASDAQ:FUSN) last released its quarterly earnings data on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative return on equity of 46.59% and a negative net margin of 4,136.55%. As a group, equities analysts anticipate that Fusion Pharmaceuticals will post -1.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Fusion Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Yarbrough Capital LLC purchased a new stake in shares of Fusion Pharmaceuticals in the 4th quarter worth $739,000. Forefront Analytics LLC lifted its holdings in shares of Fusion Pharmaceuticals by 67.8% in the 3rd quarter. Forefront Analytics LLC now owns 33,685 shares of the company’s stock worth $88,000 after buying an additional 13,610 shares during the period. Avidity Partners Management LP lifted its holdings in shares of Fusion Pharmaceuticals by 1.4% in the 3rd quarter. Avidity Partners Management LP now owns 5,781,850 shares of the company’s stock worth $15,033,000 after buying an additional 81,850 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Fusion Pharmaceuticals in the 4th quarter worth $80,000. Finally, Federated Hermes Inc. lifted its holdings in shares of Fusion Pharmaceuticals by 0.5% in the 3rd quarter. Federated Hermes Inc. now owns 10,683,789 shares of the company’s stock worth $27,778,000 after buying an additional 50,000 shares during the period. Institutional investors own 72.85% of the company’s stock.

Fusion Pharmaceuticals Company Profile

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.